Advertisement covers The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)

CROI 2012: HIV/HCV Coinfected People See Improved HCV Cure Rates With Victrelis

March 26, 2012

Results from a small study of 100 co-infected people treated with Victrelis + pegylated interferon + ribavirin showed that 61% had undetectable viral loads at 12 weeks after stopping their hepatitis C treatment.

All study participants were given pegylated interferon + ribavirin for the first 4 weeks of treatment. About 2/3 had Victrelis added to their regimen for the next 44 weeks while the other third continued on pegylated interferon + ribavirin alone. Nearly all participants were on a boosted protease inhibitor HIV regimen.

The average age of the participants was 44, and 31% were women. Most people had high HCV viral loads, while 5% had cirrhosis. Nearly 65% had HCV genotype 1a while the others had 1b. CD4 counts averaged 580 and all had undetectable HIV viral load.

The following chart describes 12-week post-treatment undetectable HCV viral loads (B/PR = Victrelis + pegylated interferon + ribavirin):

Undetectable HCV B/PR PR
4 wks 4.7% 8.8%
8 wks 37.5% 14.7%
12 wks 56.5% 25.0%
24 wks 70.5% 34.4%
48 wks 65.6% 29.4%
12 wks post 60.7% 26.5%

The following details should be noted about this study:

  • Two people saw their HCV return after being undetectable at week 48.
  • HIV viral loads became detectable in 3 people taking Victrelis.
  • CD4 counts tended to decrease in everyone; however, the CD4% did not change.
  • High rates of side effects were seen in the Victrelis group, including bad taste (28%), vomiting (28%), diarrhea (28%), anemia (41%), fever (36%), headache (23%), appetite loss (34%) and fatigue (36%). Serious anemia occurred in 5% and low neutrophil counts (27%).

A larger study will start enrolling by the end of the year.

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.